PMV Pharmaceuticals (PMVP) Stock Price, News & Analysis

Company Overview

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

Key Stats

• Today's Range: $1.20 to $1.29
• 50-Day Range: $1.07 to $1.42
• 52-Week Range: $1.02 to $1.88
• Volume: 288,306 shs
• Average Volume: 479,562 shs
• Market Capitalization: $64.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Moderate Buy

PMV Pharmaceuticals Stock Analysis - MarketRank™

PMV Pharmaceuticals scored higher than 65% of companies evaluated by MarketBeat, and ranked 279th out of 914 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

PMV Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

PMV Pharmaceuticals has a consensus price target of $4.00, representing about 223.1% upside from its current price of $1.24.

Amount of Analyst Coverage

PMV Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for PMV Pharmaceuticals are expected to grow in the coming year, from ($1.38) to ($1.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of PMV Pharmaceuticals is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of PMV Pharmaceuticals is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

PMV Pharmaceuticals has a P/B Ratio of 0.92. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.67% of the float of PMV Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

PMV Pharmaceuticals has a short interest ratio ("days to cover") of 5.92.

Change versus previous month

Short interest in PMV Pharmaceuticals has recently decreased by 5.63%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PMV Pharmaceuticals does not currently pay a dividend.

Dividend Growth

PMV Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: -0.21

News Sentiment

PMV Pharmaceuticals has a news sentiment score of -0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for PMV Pharmaceuticals this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added PMV Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, PMV Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.15% of the stock of PMV Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

90.20% of the stock of PMV Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 9/03/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PMVP
• CIK: 1699382
• Web: www.pmvpharma.com
• Phone: 609-642-6670
• Fax: N/A
• Employees: 50
• Year Founded: 2013

Price Target and Rating

• Average Price Target for PMV Pharmaceuticals: $4.00
• High Price Target: $5.00
• Low Price Target: $3.00
• Potential Upside/Downside: +227.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$77.74 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -78.11%
• Return on Assets: -70.13%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.70
• Quick Ratio: 7.70

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.34 per share
• Price / Book: 0.91

Miscellaneous

• Outstanding Shares: 53,460,000
• Free Float: 48,032,000
• Market Cap: $65.38 million
• Optionable: Optionable
• Beta: 1.37